Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Update

Xilio Therapeutics, Inc. (NASDAQ:XLOGet Free Report) was the recipient of a significant growth in short interest during the month of April. As of April 15th, there was short interest totalling 379,500 shares, a growth of 600.2% from the March 31st total of 54,200 shares. Approximately 4.4% of the shares of the stock are sold short. Based on an average trading volume of 1,170,000 shares, the days-to-cover ratio is currently 0.3 days.

Xilio Therapeutics Trading Up 7.9 %

XLO opened at $1.09 on Friday. The firm has a market capitalization of $37.57 million, a PE ratio of -0.39 and a beta of -0.12. The firm’s 50-day moving average price is $0.92 and its 200 day moving average price is $1.03. Xilio Therapeutics has a twelve month low of $0.49 and a twelve month high of $3.40.

Xilio Therapeutics (NASDAQ:XLOGet Free Report) last posted its earnings results on Monday, April 1st. The company reported ($0.64) earnings per share for the quarter. As a group, analysts predict that Xilio Therapeutics will post -1.53 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Xilio Therapeutics news, major shareholder Gilead Sciences, Inc. purchased 485,250 shares of the stock in a transaction that occurred on Tuesday, April 2nd. The shares were purchased at an average cost of $0.76 per share, for a total transaction of $368,790.00. Following the completion of the transaction, the insider now owns 7,345,473 shares of the company’s stock, valued at approximately $5,582,559.48. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 4.60% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Xilio Therapeutics

An institutional investor recently bought a new position in Xilio Therapeutics stock. PFG Investments LLC acquired a new position in Xilio Therapeutics, Inc. (NASDAQ:XLOFree Report) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 30,000 shares of the company’s stock, valued at approximately $32,000. PFG Investments LLC owned about 0.09% of Xilio Therapeutics as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 54.29% of the company’s stock.

Xilio Therapeutics Company Profile

(Get Free Report)

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, discovers and develops tumor-activated immuno-oncology therapies. Its checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 1 clinical trial for patients with advanced solid tumors.

Further Reading

Receive News & Ratings for Xilio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xilio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.